A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF AKCEA APOCIII LRX ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS)

Registry ID

ISIS 678354-CS3

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

IONIS PHARMACEUTICALS INC

Start date

2022-03-24

Completion date

2023-04-11

Last update

2020-10-01

Conditions

• FAMILIAL CHYLOMICRONEMIA SYNDROME

Related clinical trials

• AN OPEN-LABEL SAFETY STUDY OF AKCEA-APOCIII-LRX ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) PREVIOUSLY TREATED WITH VOLANESORSEN (ISIS 304801)
• AN OPEN-LABEL EXTENSION STUDY OF AKCEA-APOCIII-LRX ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS)

View on source registry